HI
BPMC

HBK Investments’s Blueprint Medicines BPMC Stock Holding History

HBK Investments’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-13,900
Closed -$1.11M – 655
2019
Q1 		$1.11M Buy
+13,900
New +$1.03M 0.01% 651
2018
Q4 		– Sell
-52,951
Closed -$4.13M – 1202
2018
Q3 		$4.13M Sell
52,951
-20,634
-28% -$1.43M 0.03% 342
2018
Q2 		$4.67M Buy
73,585
+60,429
+459% +$4.81M 0.03% 293
2018
Q1 		$1.21M Buy
13,156
+2,461
+23% +$212K 0.01% 581
2017
Q4 		$807K Sell
10,695
-5,991
-36% -$422K 0.01% 654
2017
Q3 		$1.16M Sell
16,686
-26,625
-61% -$1.42M 0.01% 592
2017
Q2 		$2.19M Buy
43,311
+8,311
+24% +$353K 0.01% 395
2017
Q1 		$1.4M Buy
+35,000
New +$1.25M 0.01% 379

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

HBK Investments's BPMC Position: Q2 2019 in Review

HBK Investments sold out of Blueprint Medicines (BPMC) in Q2 2019, closing a stake of 13,900 shares — an estimated $1.11M sold.

HBK Investments first reported a position in BPMC in Q1 2017 and held it in 8 quarters. The position peaked at $4.67M in Q2 2018. 220 funds tracked by Wall St. Rank hold BPMC as of Q2 2019.

  • HBK Investments reported no remaining Blueprint Medicines position as of Q2 2019 after selling out during the quarter.
  • HBK Investments sold 13,900 Blueprint Medicines shares in Q2 2019, an estimated $1.11M.
  • HBK Investments first reported a position in Blueprint Medicines in Q1 2017 and held it in 8 quarters.
  • HBK Investments's Blueprint Medicines position peaked at $4.67M in Q2 2018.
  • 220 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.